|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||332.60 - 337.75|
|52-week range||290.55 - 374.70|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||20.13|
|Earnings date||22 Jul 2021|
|Forward dividend & yield||9.10 (2.64%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
If the COVID mutation takes a turn for the worse, what stocks will protect your port? Our trio of Fools has three suggestions.
Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.
New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the ability to swallowEvrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries worldwideFurther presentations included data from studies supporting the efficacy, safety, and durability of gene therapy, SRP-9001, in the treatment of Duchenne muscular dystrophy (DMD) Basel, 24 September 2021 - Roch